



Patent Issued for Healionics' STAR[®] Biomaterial

Seattle, WA (July 5, 2011) – Healionics Corporation announced today that the United States Patent and Trademark Office has issued Patent No. 7,972,628, "Novel Porous Biomaterials," for the STAR[®] Biomaterial technology. STAR[®] aims to improve biointegration of implanted medical devices by inducing a unique healing response at the tissue-implant interface, promoting angiogenesis and reducing fibrous encapsulation.

The patent is licensed exclusively to Healionics from the University of Washington. It forms the intellectual property foundation for the company, with structure claims on porous biomaterials with pore sizes within an optimized size range that gives STAR[®] biomaterial its unique biointegration properties.

Dr. Andrew Marshall, Healionics' Principal Scientist and co-inventor of STAR[®], commented, "In comparison with other biomaterials on the market, STAR[®] offers a remarkable combination of biointegration and versatility. The patent issuance is an important step in protecting our intellectual property as we progress toward commercialization of this technology."

"This represents a major milestone for Healionics and directly bolsters our iSTAR Medical ophthalmic device program," stated CEO Michel Alvarez.

About Healionics Corporation

Healionics is a biomaterials technology company whose flagship STAR[®] Biomaterial aims to solve the historic "device-to-tissue" interface problem of long-term medical implants. Better healing and functioning implants are key to improving patient well-being while reducing the ballooning \$50 billion per year in global healthcare costs attributed to implant failures. STAR Biomaterial has shown promising results in reducing fibrosis, enhancing biointegration, and resisting infection, addressing several common causes for failure of long-term implants. www.healionics.com

About iSTAR Medical

iSTAR Medical SA is a Belgium-based spinout of Healionics Corporation. Its mission is to improve the lives of patients suffering from eye diseases and disorders. iSTAR's initial focus is to develop ophthalmic implants made from STAR Biomaterial for treating glaucoma.. www.istarmed.com

#

Contact:
Julie Rathbun
Rathbun Communications, Inc.
(206) 769-9219
Julie@rathbuncomm.com